Exploring Advantages to Third-Generation TKIs in Lung Cancer
Sukhmani Padda, MD, discusses how third-generation tyrosine kinase inhibitors compare to the first- and second-generation TKIs.
Sukhmani Padda, MD, assistant professor of medicine at Stanford University, discusses how third-generation EGFR tyrosine kinase inhibitors (TKIs) compare to the first- and second-generation TKIs.
Osimertinib (Tagrisso) is currently the only approved third-generation TKI, but this agent has dramatically changed the treatment landscape in lung cancer, says Padda.
Unlike earlier generation TKIs, the third-generation TKIs select for activity againstT709M
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
